Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 11:16:11795549221134832.
doi: 10.1177/11795549221134832. eCollection 2022.

Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma

Jin-Tao Huang  1 , Shuai Zhang  1 , Yi-Han Yang  1 , Zi-Chen Zhang  1 , Nan Jiang  1 , Wan-Ci Li  1 , Jian Shen  1 , Bin-Yan Zhong  1 , Xiao-Li Zhu  1
Affiliations
Review

Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma

Jin-Tao Huang et al. Clin Med Insights Oncol. .

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and deadly malignancies worldwide. Approximately, 80% of patients are initially diagnosed at intermediate or advanced stages, which means that curative therapies are unable to be performed. In most cases, systemic treatment is ineffective, especially when conventional cytotoxic agents are used. Sorafenib has been the only systemic agent proven to be effective in treating advanced HCC for over a decade. The rapid development of immunotherapy has remarkably revolutionized the management of advanced HCC. Besides, the combination of immunotherapy with molecular targeted agents or locoregional treatments is emerging as an effective tool for enhancing immunity. In the review, an overview of immunotherapy and its combination therapies for HCC is presented.

Keywords: Hepatocellular carcinoma; combination therapy; immune checkpoint inhibitor; immunotherapy; interventional therapy; molecular targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
First treatment option, expected survival and ongoing key randomized trials involving immunotherapy for hepatocellular carcinoma. AFP indicates α-fetoprotein; BSC, best supportive care; D-TACE, drug-eluting bead transarterial chemoembolization; PS, performance status; TACE, transarterial chemoembolization.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. doi:10.3322/caac.21660. - DOI - PubMed
    1. Llovet JM, Kelley RK, Villanueva A, et al.. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. doi:10.1038/s41572-020-00240-3. - DOI - PubMed
    1. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450-1462. doi:10.1056/NEJMra1713263. - DOI - PubMed
    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. doi:10.1038/s41575-019-0186-y. - DOI - PMC - PubMed
    1. Kudo M, Finn RS, Qin S, et al.. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173. doi:10.1016/S0140-6736(18)30207-1. - DOI - PubMed

LinkOut - more resources